Cancer
Malignant Cervical Neoplasm
CI-CAN-00007992Explore in graph →
Top-level506 active trials4 approved drugs14 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00007992Explore in graph →
Clinical trials
1,994 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (181)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05337735 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | suspended | Phase 2 | 140 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07345897 | Emergency Department-based Cervical Cancer Screening Through Self-sampling | recruiting | N/A | 200 | University of RochesterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05440760 |
| Using Virtual Reality Technology to Improve Patient Experience and Quality of Care During Brachytherapy |
| recruiting |
| N/A |
| 20 |
| University of ArkansasOTHER |
| 1 |
| Apr 30, 2026 |
| clinicaltrials |
| NCT06628388 | Nurse-led Primary Healthcare Intervention Model in Women's Health Management in Hong Kong(JCDATAZONEWH) | active not recruiting | N/A | 1,728 | The University of Hong KongOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07547267 | The Effect of Vaginal Dilator Use | completed | N/A | 80 | Istanbul Aydın UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04185389 | Long-Term Follow-Up of HPV FOCAL Participants(HPV FOCAL) | completed | — | 1,710 | University of British ColumbiaOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT04242823 | Primary HPV-based Cervical Cancer Screening Algorithms in Botswana | active not recruiting | N/A | 3,000 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT04716127 | A Proximity-incentive Strategy for Cervical Cancer Screening(RIDECA) | completed | N/A | 656 | University Hospital, MontpellierOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07338487 | A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer | recruiting | Phase 1 | 88 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06157151 | PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer | recruiting | Phase 2 | 24 | Precigen, IncINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07447895 | Early Pelvic Floor Physical Therapy for Women Undergoing Pelvic Radiation for Gynecologic Malignancies | recruiting | N/A | 28 | University of CincinnatiOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03970083 | A Pilot Study of Quantitative Tumor Oxygen Measurements in Cervical Cancer | active not recruiting | — | 10 | Brigham and Women's HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06769152 | A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors | recruiting | Phase 2 | 190 | Shanghai Henlius BiotechINDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03556839 | Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix(BEATcc) | completed | Phase 3 | 410 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 8 | Apr 21, 2026 | clinicaltrials |
| NCT07407647 | Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer | recruiting | Phase 2 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT02328872 | Compass - Randomised Controlled Trial of Primary HPV Testing for Cervical Screening in Australia(Compass) | active not recruiting | N/A | 76,181 | VCS FoundationOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07223424 | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy(PSI-Immune) | recruiting | Phase 2 | 880 | Diwakar DavarOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04580771 | A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial | active not recruiting | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04678414 | Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer | active not recruiting | — | 1,410 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05489978 | Effectiveness of a Cervical Cancer Stigma Reduction Intervention Program on Cancer Stigma Score and Cervical Cancer Screening Uptake in Nepal | completed | N/A | 310 | Kathmandu University School of Medical SciencesOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06799637 | Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments | recruiting | Phase 1 / Phase 2 | 350 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07168200 | A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer | recruiting | Phase 3 | 720 | Shanghai Shengdi Pharmaceutical Co., LtdINDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06527456 | Intervention With General Practitioners to Improve Women's Participation in Cervical Cancer Screening(INDIGO) | recruiting | N/A | 11,200 | Centre Hospitalier Intercommunal CreteilOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03115398 | A Simple Walking Program to Enhance Concurrent Chemoradiotherapy Delivery | completed | N/A | 166 | Montefiore Medical CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07062016 | Molecular and ctDNA Characterization of High-Risk Endometrial Cancer | recruiting | — | 100 | Mayo ClinicOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05570422 | A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 | recruiting | Phase 1 | 70 | Kortuc, Inc.INDUSTRY | 3 | Apr 8, 2026 | clinicaltrials |
| NCT06973161 | ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors | completed | — | 140 | AstraZenecaINDUSTRY | 12 | Apr 8, 2026 | clinicaltrials |
| NCT06444815 | A Study of VET3-TGI in Patients With Solid Tumors(STEALTH-001) | recruiting | Phase 1 | 60 | KaliVir ImmunotherapeuticsINDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07516210 | Adaptive Radiotherapy for Safe Hypofractionation(ART-Hypo) | not yet recruiting | Phase 2 | 264 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07418749 | A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer | recruiting | Phase 3 | 398 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03612791 | Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab(ATEZOLACC) | completed | Phase 2 | 189 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04588402 | Impact of HPV Vaccination on Prevention of Cervical HPV Infection in Sikkim, India(HPV-Vac-S) | recruiting | — | 5,500 | International Agency for Research on CancerOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06919627 | Negative HPV Test Results on Infinity/GeneXpert® With the Presence of a Late Amplification Signal: What Does This Mean ? (PaPCR)(PaPCR) | completed | — | 45 | University Hospital, BrestOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03614949 | SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer | active not recruiting | Phase 2 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05645146 | Enhancing Long-Term Smoking Abstinence Among Cervical Cancer Survivors (Project ACCESS) | active not recruiting | N/A | 360 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04093388 | Self-Collection of the Pap Smear as Agency: A Novel Way to Improve Refractory Low Cervical Cancer Screening Rates in Rural Alabama(Pap) | recruiting | N/A | 250 | University of Alabama at BirminghamOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04122235 | The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study(LETSGO) | completed | N/A | 755 | Sorlandet Hospital HFOTHER_GOV | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07256236 | SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer | recruiting | Phase 2 | 89 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 30, 2026 | clinicaltrials |
| NCT02122185 | Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 111 | University of ChicagoOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02865837 | Effect of Bladder Distension on Dosimetry in Brachytherapy of Cervical Cancer(VESICOL) | completed | N/A | 22 | Institut de Cancérologie de LorraineOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03894215 | RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer | terminated | Phase 2 | 211 | Agenus Inc.INDUSTRY | 7 | Mar 27, 2026 | clinicaltrials |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 115 | SOTIO Biotech AGINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT05286034 | Using Artificial Intelligence-based ChatBot to Improve Women's Participation to Cervical Cancer Screening Programme(AppDate-You) | recruiting | N/A | 3,000 | International Agency for Research on CancerOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06836869 | Modified Tumor-free Techniques Operation to Cervical Cancer(MOTTO) | recruiting | N/A | 524 | Peking Union Medical College HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07276360 | Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda(HypoRTCx-UG) | recruiting | Phase 2 | 278 | Uganda Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07497074 | JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer | not yet recruiting | Phase 2 | 78 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04226313 | Self-sampling for Non-attenders to Cervical Cancer Screening(KOPRETINA) | recruiting | N/A | 15,000 | The Institute of Molecular and Translational Medicine, Czech RepublicOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04919629 | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion | recruiting | Phase 2 | 60 | Roswell Park Cancer InstituteOTHER | 1 | Mar 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 4, 2026source: clinicaltrials